Pharma BD Deal Intelligence
Bristol Myers Squibb licenses Agenus bispecific antibody program AGEN1777 in potential $1.56 billion deal for cancer immunotherapy development
BMS will make an upfront payment of $200m to Agenus for exclusive license to bispecific antibody AGEN1777, eligible for up to $1.36bn in milestones
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
BMS licensed Agenus' next-generation anti-CTLA-4 antibody AGEN1181 designed to enhance anti-tumor immunity beyond ipilimumab.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Agenus Inc. (this deal) | 2017 | $1.6B | 45 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2017 deals · Bristol-Myers Squibb Company deals · Oncology deals